Active, Not Recruiting
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
NCT03962465
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
- Locations
-
- Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
- University of Virginia Charlottesville, Virginia, United States
- VCU Massey Cancer Center Richmond, Virginia, United States
- University of Wisconsin Madison, Wisconsin, United States